Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Shares Issued (2023 - 2025)

CG Oncology's Shares Issued history spans 3 years, with the latest figure at -$42.5 million for Q4 2025.

  • For Q4 2025, Shares Issued fell 119.07% year-over-year to -$42.5 million; the TTM value through Dec 2025 reached $6.9 million, down 98.91%, while the annual FY2025 figure was $6.5 million, 98.41% down from the prior year.
  • Shares Issued reached -$42.5 million in Q4 2025 per CGON's latest filing, down from $48.7 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $406.4 million in Q1 2024 to a low of -$406.3 million in Q2 2024.
  • Average Shares Issued over 3 years is $53.2 million, with a median of $472000.0 recorded in 2023.
  • The largest YoY upside for Shares Issued was 597561.76% in 2024 against a maximum downside of 246362.42% in 2024.
  • A 3-year view of Shares Issued shows it stood at $262000.0 in 2023, then surged by 85052.67% to $223.1 million in 2024, then plummeted by 119.07% to -$42.5 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Shares Issued are -$42.5 million (Q4 2025), $48.7 million (Q3 2025), and $19000.0 (Q2 2025).